Therapeutic efficacy of ruxolitinib combined with low-dose hormone in aGVHD after allogeneic hematopoietic stem cell transplantation
10.13303/j.cjbt.issn.1004-549x.2026.04.013
- VernacularTitle:芦可替尼联合小剂量激素治疗移植后aGVHD的疗效观察
- Author:
Yue HU
1
;
Xupai ZHANG
2
;
Sihan LAI
2
;
Shan ZHANG
2
;
Lei MA
2
;
Xiao WANG
2
;
Yan DENG
2
;
Ying HAN
2
;
Ying HE
2
;
Guangcui HE
2
;
Hai YI
2
Author Information
1. The North Sichuan Medical College, Nanchong 637100, China; Department of Hematology, The General Hospital of Western Theater Command, PLA, Chengdu 610083, China
2. Department of Hematology, The General Hospital of Western Theater Command, PLA, Chengdu 610083, China
- Publication Type:Journal Article
- Keywords:
ruxolitinib;
glucocorticoid;
allogeneic hematopoietic stem cell transplantation (allo-HSCT);
acute graft versus host disease (aGVHD)
- From:
Chinese Journal of Blood Transfusion
2026;39(4):506-512
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the efficacy and safety of ruxolitinib combined with low-dose hormone for patients with acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods: Thirty patients with aGVHD after allo-HSCT admitted to the Department of Hematology of the General Hospital of Western Theater Command from November 2021 to November 2024 were retrospectively analyzed. All patients were treated with low-dose hormone (methylprednisolone 0.3-1 mg kg
-d
) combined with ruxolitinib 5-10 mg d
. The efficacy and adverse reactions were observed during the follow-up period to analyze the survival outcomes of the patients. Results: A total of 30 patients with aGVHD after allo-HSCT were included in this study, consisting of 15 (50%) males and 15 (50%) females with a median age of 34 year-old (ranging from 14 to 62). Classification by disease type: there were 18 cases of acute myeloid leukemia, 4 cases of acute lymphoblastic leukemia, 4 cases of aplastic anemia, and 4 cases of myelodysplastic syndrome. Classification by aGVHD severity: there were 27 cases (90%) of Ⅱ-Ⅳ degree aGVHD and 11 cases (36.7%) of Ⅲ-Ⅳ degree aGVHD. Ruxolitinib in combination with low-dose glucocorticoid treatment yield responses in 28 (93.3%) patients, of which 27 (90%) achieved complete remission (CR), while 1 (3.3%) showed partial remission (PR). One patient (3.3%) had no response (NR), and 1 patient (3.3%) exhibited progressed disease (PD). Overall survival (OS) at 1 year of transplantation was 73.9% (95%CI 49.5% to 87.7%), progression-free survival (PFS) was 93.3% (95%CI 75.9% to 98.3%), non-relapse mortality (NRM) was 20.6% (95%CI 7.9% to 47.4%), and median survival time was 27.6 months. Conclusion: Ruxolitinib combined with low-dose hormones is safe and effective in the treatment of aGVHD after allo-HSCT.
